JP2021522241A - 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 - Google Patents

抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 Download PDF

Info

Publication number
JP2021522241A
JP2021522241A JP2020559390A JP2020559390A JP2021522241A JP 2021522241 A JP2021522241 A JP 2021522241A JP 2020559390 A JP2020559390 A JP 2020559390A JP 2020559390 A JP2020559390 A JP 2020559390A JP 2021522241 A JP2021522241 A JP 2021522241A
Authority
JP
Japan
Prior art keywords
subject
osmrβ
pruritus
antibody
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020559390A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019229525A5 (https=
JP2021522241A5 (https=
Inventor
ジョン パオリーニ，
ジョン パオリーニ，
ローハン ガンディ，
ローハン ガンディ，
ザマネ ミカク，
ザマネ ミカク，
Original Assignee
キニクサ ファーマシューティカルズ， リミテッド
キニクサ ファーマシューティカルズ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キニクサ ファーマシューティカルズ， リミテッド, キニクサ ファーマシューティカルズ， リミテッド filed Critical キニクサ ファーマシューティカルズ， リミテッド
Publication of JP2021522241A publication Critical patent/JP2021522241A/ja
Publication of JPWO2019229525A5 publication Critical patent/JPWO2019229525A5/ja
Publication of JP2021522241A5 publication Critical patent/JP2021522241A5/ja
Priority to JP2024066665A priority Critical patent/JP2024096933A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020559390A 2018-04-25 2019-04-25 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療 Withdrawn JP2021522241A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024066665A JP2024096933A (ja) 2018-04-25 2024-04-17 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201862662607P 2018-04-25 2018-04-25
US62/662,607 2018-04-25
US201862718324P 2018-08-13 2018-08-13
US62/718,324 2018-08-13
US201862765033P 2018-08-16 2018-08-16
US62/765,033 2018-08-16
US201862731618P 2018-09-14 2018-09-14
US62/731,618 2018-09-14
US201862757047P 2018-11-07 2018-11-07
US62/757,047 2018-11-07
US201862775350P 2018-12-04 2018-12-04
US62/775,350 2018-12-04
US201962789434P 2019-01-07 2019-01-07
US62/789,434 2019-01-07
US201962794356P 2019-01-18 2019-01-18
US62/794,356 2019-01-18
PCT/IB2019/000619 WO2019229525A2 (en) 2018-04-25 2019-04-25 TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024066665A Division JP2024096933A (ja) 2018-04-25 2024-04-17 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療

Publications (3)

Publication Number Publication Date
JP2021522241A true JP2021522241A (ja) 2021-08-30
JPWO2019229525A5 JPWO2019229525A5 (https=) 2022-05-06
JP2021522241A5 JP2021522241A5 (https=) 2022-05-06

Family

ID=68234020

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559390A Withdrawn JP2021522241A (ja) 2018-04-25 2019-04-25 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療
JP2024066665A Pending JP2024096933A (ja) 2018-04-25 2024-04-17 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024066665A Pending JP2024096933A (ja) 2018-04-25 2024-04-17 抗ｏｓｍｒβ抗体の送達による皮膚疾患又は障害の治療

Country Status (12)

Country Link
US (3) US20210054085A1 (https=)
EP (1) EP3784347A2 (https=)
JP (2) JP2021522241A (https=)
KR (2) KR102849806B1 (https=)
CN (2) CN121818914A (https=)
AU (2) AU2019276779A1 (https=)
BR (1) BR112020021739A2 (https=)
CA (1) CA3096582A1 (https=)
IL (1) IL326629A (https=)
MX (2) MX2020011172A (https=)
SG (1) SG11202010034WA (https=)
WO (1) WO2019229525A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI871349B (zh) * 2020-09-01 2025-02-01 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之透析搔癢症的預防用及/或治療用醫藥組合物
US20230391878A1 (en) * 2020-09-01 2023-12-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520619A (ja) * 2013-05-30 2016-07-14 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． オンコスタチンｍ受容体抗原結合タンパク質

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188500A1 (en) * 2005-02-14 2006-08-24 Leung Donald Y Methods of predicting therpeutic response in atopic dermatitis to IL-31 antagonists
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
JP6214010B2 (ja) * 2012-05-11 2017-10-18 公立大学法人和歌山県立医科大学 抗オンコスタチンｍ受容体ベータ抗体
TWI755763B (zh) * 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20170132143A (ko) * 2015-01-29 2017-12-01 옥스포드 유니버시티 이노베이션 리미티드 바이오마커
KR20170134748A (ko) * 2015-04-14 2017-12-06 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520619A (ja) * 2013-05-30 2016-07-14 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． オンコスタチンｍ受容体抗原結合タンパク質

Also Published As

Publication number Publication date
EP3784347A2 (en) 2021-03-03
WO2019229525A2 (en) 2019-12-05
JP2024096933A (ja) 2024-07-17
CA3096582A1 (en) 2019-12-05
MX2020011172A (es) 2021-01-29
US20240101690A1 (en) 2024-03-28
IL326629A (en) 2026-04-01
CN121818914A (zh) 2026-04-10
WO2019229525A3 (en) 2020-03-19
CN112533675A (zh) 2021-03-19
US20210054085A1 (en) 2021-02-25
MX2025006542A (es) 2025-07-01
US20250236676A1 (en) 2025-07-24
AU2026201985A1 (en) 2026-04-02
KR20250127348A (ko) 2025-08-26
KR20210018808A (ko) 2021-02-18
BR112020021739A2 (pt) 2021-01-26
KR102849806B1 (ko) 2025-08-22
AU2019276779A1 (en) 2020-12-10
SG11202010034WA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
Hoffman et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study
Mabuchi et al. CCR6 is required for epidermal trafficking of γδ-T cells in an IL-23-induced model of psoriasiform dermatitis
Den Broeder et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
Emery et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
ES2733712T3 (es) Métodos para tratar la espondilitis anquilosante utilizando anticuerpos anti-IL-17
US20250236676A1 (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
JP2021193121A (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
RU2714919C2 (ru) Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
KR20210145295A (ko) Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
Sadura-Sieklucka et al. Effects of whole body cryotherapy in patients with rheumatoid arthritis considering immune parameters
JP2013100313A (ja) Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
CN119095617A (zh) 用于治疗患有头皮斑块型银屑病的受试者的方法
TW202045537A (zh) 化膿性汗腺炎的治療
JP2023522196A (ja) 化膿性汗腺炎の治療
CN113453759A (zh) 治疗巨细胞动脉炎
TWI850365B (zh) 治療克隆氏症(crohn's disease)的方法
CA3080665A1 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
JP2021147383A (ja) アトピー性皮膚炎及び関連障害を処置するための方法
KR100756974B1 (ko) 알레르기 질환 및 만성염증성 질환의 치료를 위한 약학적 조성물 및 키트
JP2020535140A (ja) インターロイキン−１受容体アンタゴニスト融合タンパク質の送達による炎症状態の治療
TWI856006B (zh) 具有中至重度表皮脫落之異位性皮膚炎之治療
WO2020036833A1 (en) Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
JP2021031482A (ja) 掻痒治療剤
JP2024515816A (ja) Ａｄａｍｔｓ結合免疫グロブリンの投与の方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240508

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20240510